Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the thirteen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $27.00.
Several equities research analysts recently weighed in on the stock. Truist Financial initiated coverage on shares of Nurix Therapeutics in a research report on Wednesday, July 31st. They issued a "buy" rating and a $36.00 price target on the stock. Royal Bank of Canada boosted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the company an "outperform" rating in a research report on Friday, July 12th. Piper Sandler reaffirmed an "overweight" rating and set a $35.00 price objective on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. Robert W. Baird started coverage on shares of Nurix Therapeutics in a research note on Friday, September 6th. They issued an "outperform" rating and a $26.00 price objective for the company. Finally, Oppenheimer upped their target price on Nurix Therapeutics from $27.00 to $30.00 and gave the company an "outperform" rating in a research note on Wednesday, September 4th.
View Our Latest Research Report on NRIX
Shares of NASDAQ:NRIX opened at $21.97 on Thursday. The company has a market cap of $1.08 billion, a PE ratio of -7.52 and a beta of 2.22. Nurix Therapeutics has a 12-month low of $4.22 and a 12-month high of $26.31. The stock has a 50 day moving average of $23.16 and a 200 day moving average of $18.80.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Thursday, July 11th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.08). The company had revenue of $12.09 million during the quarter, compared to analysts' expectations of $19.35 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. Equities research analysts predict that Nurix Therapeutics will post -2.95 earnings per share for the current fiscal year.
In other news, insider Christine Ring sold 5,760 shares of the stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $21.43, for a total transaction of $123,436.80. Following the transaction, the insider now owns 24,592 shares in the company, valued at approximately $527,006.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In other Nurix Therapeutics news, insider Christine Ring sold 5,760 shares of the business's stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $21.43, for a total transaction of $123,436.80. Following the completion of the sale, the insider now directly owns 24,592 shares in the company, valued at approximately $527,006.56. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Houte Hans Van sold 20,000 shares of the firm's stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now owns 31,002 shares in the company, valued at approximately $781,870.44. The disclosure for this sale can be found here. Over the last three months, insiders have sold 59,815 shares of company stock valued at $1,424,931. Corporate insiders own 7.20% of the company's stock.
Several hedge funds and other institutional investors have recently modified their holdings of NRIX. Driehaus Capital Management LLC purchased a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $26,778,000. Redmile Group LLC increased its position in Nurix Therapeutics by 37.7% during the first quarter. Redmile Group LLC now owns 4,483,016 shares of the company's stock worth $65,900,000 after purchasing an additional 1,226,497 shares during the last quarter. Samlyn Capital LLC purchased a new position in Nurix Therapeutics during the second quarter worth about $12,177,000. Ikarian Capital LLC acquired a new position in Nurix Therapeutics in the 1st quarter valued at about $4,410,000. Finally, Candriam S.C.A. grew its stake in shares of Nurix Therapeutics by 30.5% in the 2nd quarter. Candriam S.C.A. now owns 1,164,246 shares of the company's stock valued at $24,297,000 after buying an additional 272,136 shares during the period.
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Nurix Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nurix Therapeutics wasn't on the list.
While Nurix Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.